Filana Therapeutics, Inc. (FLNA) stock
FLNANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.64+0.08 (+14.52%)
Close on Nov 20, 2026Market cap $30.98MP/E –Yield –
Filana Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Filana Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$45.97M. For fiscal 2025 it was -$95.39M. The highest annual figure on record is $31.37M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$95.39M | – |
| FY2024 | Dec 31, 2024 | -$141.45M | – |
| FY2023 | Dec 31, 2023 | -$105.96M | – |
| FY2022 | Dec 31, 2022 | -$80.02M | – |
| FY2021 | Dec 31, 2021 | -$32.87M | – |
| FY2020 | Dec 31, 2020 | -$6.45M | – |
| FY2019 | Dec 31, 2019 | -$4.96M | – |
| FY2018 | Dec 31, 2018 | -$6.66M | – |
| FY2017 | Dec 31, 2017 | -$11.95M | – |
| FY2016 | Dec 31, 2016 | -$14.96M | – |
| FY2015 | Dec 31, 2015 | -$14.20M | – |
| FY2014 | Dec 31, 2014 | -$12.43M | -139.6% |
| FY2013 | Dec 31, 2013 | $31.37M | – |
| FY2012 | Dec 31, 2012 | -$3.90M | – |
| FY2011 | Dec 31, 2011 | -$3.51M | – |
| FY2010 | Dec 31, 2010 | -$13.70M | – |
| FY2009 | Dec 31, 2009 | -$6.75M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.17M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.55M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$45.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$24.59M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.49M | – |
| Q3 FY2024 | Sep 30, 2024 | -$30.62M | – |
| Q2 FY2024 | Jun 30, 2024 | -$61.40M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.93M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.79M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.88M | – |
| Q2 FY2023 | Jun 30, 2023 | -$28.78M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.51M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.94M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.35M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.92M | – |
| Q1 FY2022 | Mar 31, 2022 | -$17.82M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.44M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.75M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.14M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.53M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.62M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.44M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.16M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.22M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.58M | – |
| Q3 FY2019 | Sep 30, 2019 | -$779.00K | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.15M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.45M | – |
| Q4 FY2018 | Dec 31, 2018 | -$750.00K | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.28M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.46M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.17M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.42M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.60M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.17M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.76M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.54M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.54M | – |
See a number that looks wrong?